Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma

The investigators hypothesize that the addition of Tislelizumab after definitive local therapy for locally advanced inoperable Hepatocellular carcinoma (HCC) will synergize with local therapy as well as treat micro metastatic disease and improve one year progression-free survival rates for participants and optimize local control.

Trial Details

NCT ID
NCT05366829
Phase
PHASE2
Sponsor
Rutgers, The State University of New Jersey
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Tislelizumab
Locations (sample)
  • New Brunswick, New Jersey, United States|40.48622,-74.45182
  • The Bronx, New York, United States|40.84985,-73.86641

Key Eligibility Criteria

  • Each patient eligible to participate in this study must meet all the following criteria:
  • Written informed consent
  • Primary diagnosis of HCC, planned to receive radiation, treatment naïve to systemic therapy for HCC, prior TACE permitted
  • Hepatocellular carcinoma diagnosis by histologic findings and/or imaging criteria of LI-RADS 5

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →